| NCT06390410 | A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function | COMPLETED | PHASE1 | 2024-06-26 | 2024-12-07 | 2024-12-07 |
| NCT06195319 | Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects | COMPLETED | PHASE1 | 2024-02-07 | 2024-03-27 | 2024-03-27 |
| NCT05575076 | Open-label Extension for Phase 3 Clinical Trials of Simufilam | TERMINATED | PHASE3 | 2022-11-07 | 2025-01-31 | 2025-01-31 |
| NCT05352763 | Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease | TERMINATED | PHASE2 | 2022-05-12 | 2024-12-31 | 2024-12-31 |
| NCT05026177 | Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease | TERMINATED | PHASE3 | 2021-11-18 | 2024-12-30 | 2024-12-30 |
| NCT04994483 | Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease | COMPLETED | PHASE3 | 2021-11-03 | 2024-10-02 | 2024-10-02 |
| NCT04932655 | Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers | COMPLETED | PHASE1 | 2021-05-04 | 2021-05-11 | 2021-05-11 |
| NCT04388254 | Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients | COMPLETED | PHASE2 | 2020-03-24 | 2023-11-09 | 2023-11-09 |
| NCT04079803 | PTI-125 for Mild-to-moderate Alzheimer's Disease Patients | COMPLETED | PHASE2 | 2019-09-09 | 2020-03-31 | 2020-03-31 |
| NCT03748706 | PTI-125 for Mild-to-moderate Alzheimer's Disease Patients | COMPLETED | PHASE2 | 2019-03-07 | 2019-05-08 | 2019-05-08 |
| NCT03784300 | A Safety Study of PTI-125 in Healthy Volunteers | COMPLETED | PHASE1 | 2017-08-18 | 2018-03-27 | 2017-10-09 |